Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
Vial Logo

Updates

Search
All Resources
Press Releases
Videos

It’s clear the next breakthrough in obesity treatment will come from entirely new mechanisms that go beyond appetite suppression like VIAL-INHBE. Hear more from Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research.

VIAL-INHBE’s selective fat reduction and muscle preservation is a profile with meaningful clinical potential. Dr. Massimo Volpe, Professor of Cardiology at the University of Rome Sapienza, shares his perspective on why this approach could transform patient care.

Dr. Jason Fung: Treating obesity means more than weight loss – it’s about correcting metabolic disease. VIAL-INHBE can help obese and overweight populations avoid major health issues.

Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity

Read Article

Could the next generation of obesity treatments help preserve muscle and enhance fat loss? Dr. Tim Garvey (UAB) shares how INHBE inhibition could complement GLP-1 therapies for broader benefit.

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.

Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.

It’s clear the next breakthrough in obesity treatment will come from entirely new mechanisms that go beyond appetite suppression like VIAL-INHBE. Hear more from Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research.

VIAL-INHBE’s selective fat reduction and muscle preservation is a profile with meaningful clinical potential. Dr. Massimo Volpe, Professor of Cardiology at the University of Rome Sapienza, shares his perspective on why this approach could transform patient care.

Dr. Jason Fung: Treating obesity means more than weight loss – it’s about correcting metabolic disease. VIAL-INHBE can help obese and overweight populations avoid major health issues.

Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity

Read Article

Could the next generation of obesity treatments help preserve muscle and enhance fat loss? Dr. Tim Garvey (UAB) shares how INHBE inhibition could complement GLP-1 therapies for broader benefit.

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.

Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.